
ImmunityBio Secures U.S. Patents for ANKTIVA-BCG Cancer Therapy Through 2035
ImmunityBio Secures U.S. Patent Protection Through 2035 for ANKTIVA-BCG Combination Cancer Therapy ImmunityBio has announced the issuance of five United States patents covering the combination of its IL-15 receptor agonist ANKTIVA with Bacillus Calmette-Guérin for the treatment of cancer, significantly…












